Targeted Regenerative Support for Macular Degeneration
Advanced cellular therapy focused on stabilizing retinal pigment epithelium (RPE) health and microvascular support.
Stem cell therapy for Macular Degeneration (Dry AMD & Geographic Atrophy) is an investigational approach aimed at delaying RPE atrophy and photoreceptor loss. It is not an established clinical cure, and does not replace regular retinal monitoring.
Mesenchymal stem cells release pigment epithelium-derived factor (PEDF), basic fibroblast growth factor (bFGF), and anti-apoptotic neurotrophins that nourish retinal pigment epithelium cells, assisting in central vision stabilization.
The Clinical Approach
Utilizes adult mesenchymal stem cells (MSCs) and neurotrophic secretomes to help slow photoreceptor attrition, reduce localized oxidative stress, and nourish deteriorating retinal tissue.
Primary Objective
Halting rapid disease progression, supporting surviving retinal cells, and maintaining central functional vision.
Patient Eligibility & Screening Criteria
Inclusion guidelines, exclusion protocols, and multi-disciplinary ophthalmic evaluation
Forms Evaluated:
- • Dry AMD (Geographic Atrophy): Primary target for cellular neuroprotection and RPE support.
- • Wet AMD (Neovascular): Evaluated strictly as an adjunctive support only after active choroidal neovascularization (CNV) is stabilized by conventional anti-VEGF therapy.
- • Stargardt Disease: Evaluated on a case-by-case basis based on remaining foveal integrity.
Mandatory Pre-Travel Requirements:
- • Recent High-Definition Optical Coherence Tomography (HD-OCT) and Fundus Autofluorescence (FAF) scans.
- • Preserved baseline retinal architecture (therapy cannot replace completely absent or scarred foveal tissue).
- • Medical clearance for international travel.
Harvested from patient's own bone marrow; eliminates foreign cellular immunogenicity while providing rich trophic factors.
Ethically collected from screened maternal donors post-caesarean; high vitality without requiring bone marrow aspiration from the patient.
Realistic Potential Benefits & Improvements
Outcomes vary based on baseline atrophy, age, and chronicity. The primary goal is functional preservation.
Delayed Atrophy Spread
Protecting marginal retinal tissue from entering end-stage geographic atrophy.
Clinical Observation Timeline
RPE trophic rescue takes 6 to 12 weeks to influence photoreceptor metabolic balance, with visual stabilization monitored over 6 to 12 months.
Why Choose India for Ophthalmic Cellular Care?
State-of-the-art retinal diagnostics, fellowship-trained vitreoretinal surgeons, and significant cost savings
| Quality Metric | What Our Partner Centers Provide |
|---|---|
| Accreditation | JCI / NABH Infrastructure: Partnered with premier tertiary eye institutes and hospitals in major metro hubs (Delhi, Mumbai, Bengaluru). |
| Cost Advantage | Vitreoretinal Expertise: Procedures performed in sterile surgical theaters under direct supervision of experienced ophthalmologists. |
| Surgeon Leadership | Affordable Excellence: Comprehensive packages save 60%–75% compared to experimental clinics in the US or Europe, with no hidden lab charges. |
| Advanced Imaging | Ethical Patient Triage: Strict rejection policy for patients where clinical imaging shows no viable retinal structure left to salvage. |
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering single or bilateral eyes based on clinical severity and cell dosage).
(Aimed at slowing visual degeneration, neurotrophic rescue, and stabilizing functional sight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | $4,500 – $7,500 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $25,000 – $45,000 USD | 3 – 6 Months | Clinical Trial Gated |
| United Kingdom & EU | $22,000 – $38,000 USD | 2 – 5 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $32,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated International Patient Services
Complimentary Remote Triage: Direct case review by our medical board before you book flights.
Pre-Travel Teleconsultation
Medical Visa Guidance: Rapid provision of official Indian Medical Visa (e-Med Visa) invitation letters.
Visa Facilitation
Multi-Language Assistance: Dedicated language coordinators (English, Arabic, Russian, French, Spanish).
Language Interpreters
Seamless Ground Travel: Chauffeur airport pickups, drop-offs, and hospital transfers.
Post-Care Telemedicine
12-Month Remote Monitoring: Scheduled telemedicine check-ins at 1, 3, 6, and 12 months in coordination with your hometown eye doctor.
Travel, Transfers & Stay Logistics
Ensuring safe transit, comfortable partner accommodations, and accessible stays
Private Transfers
Tailored Lodging: Pre-negotiated rates at partner 4-star and 5-star serviced apartments and hotels within 10–15 minutes of the clinic.
Accessible Accommodation
Attendant Comfort: All hospital day-care and inpatient rooms include accommodation for an accompanying family member.
Local Amenities
Local Support: Assistance with local SIM cards, currency exchange, dietary-specific meals (Halal, Vegetarian, Kosher-friendly), and transport.
5-Day Clinical Schedule in India
Structured day-by-day roadmap from multimodal baseline testing to fit-to-fly departure
Day 1: Arrival & Retinal Mapping
Airport reception, hospital check-in, dilated fundus exam, repeat baseline OCT, and physician consultation.
Day 2: Targeted Cell Administration
Sterile, minimally invasive delivery (retrobulbar, targeted peribulbar, or intravenous systemic infusion under local topical anesthesia).
Day 3: Adjunctive Mitochondrial & Vision Therapies
Supportive anti-oxidative IV regimens and personalized low-vision rehabilitation planning.
Day 4: Slit-Lamp & Pressure Monitoring
Post-procedure ophthalmic examination, intraocular pressure checks, and recovery verification.
Day 5: Discharge & Travel Clearance
Comprehensive medical summary, home care protocol, and return flight clearance.
Potential Risks, Procedural Safety & Quality Protocols
Sterility release testing, risk management, and cGMP cleanroom preparation
Mild Localized Side Effects
Temporary ocular redness, mild conjunctival irritation, or transient subconjunctival ecchymosis.
Procedural Considerations
Low risk of intraocular pressure fluctuation or transient floaters, managed with routine post-procedure drops.
Quality Assurance
All cell batches undergo rigorous testing for viability, endotoxins, sterility, and genomic stability prior to administration.
cGMP Cleanroom Processing
ISO Class 5 biosafety laminar flow cleanrooms with HEPA air filtration and continuous particle monitoring.
Flow Cytometry Verification
≥95% positive ISCT surface markers (CD73, CD90, CD105) and ≤2% negative hematopoietic markers.
14-Day Sterility Release
Automated USP sterility cultures, mycoplasma PCR, and LAL endotoxin testing (<0.5 EU/ml) prior to release.
Institutional Ethics Review
Operates under independent Institutional Ethics Committees (IEC) registered with CDSCO, Government of India.
Frequently Asked Questions: Macular Degeneration Care
Authoritative medical guidance regarding cellular protocols, realistic visual outcomes, and travel
Stem cells act primarily by secreting trophic factors that nourish dying Retinal Pigment Epithelium (RPE) cells and photoreceptors. This slows down the enlargement of geographic atrophy, reduces drusen-induced metabolic stress, and preserves central visual acuity (Sung et al., 2020).
Stem cell therapy is primarily indicated for dry AMD. Patients with wet AMD must first achieve stability with anti-VEGF injections (such as Lucentis, Eylea, or Avastin) to ensure there is no active intraretinal bleeding or active choroidal neovascularization before cellular protocols are considered.
Clinical goals focus on stabilizing central vision, reducing blind spot (scotoma) intensity, improving contrast sensitivity, and enhancing reading capability under adequate lighting.
Administration involves targeted suprachoroidal, sub-Tenon, or periocular micro-injections under operating microscope guidance, ensuring sustained paracrine delivery adjacent to the posterior macular arcades.
Patients submit high-definition Spectral Domain OCT scans, fundus autofluorescence (FAF) to map atrophy boundaries, and best-corrected visual acuity (BCVA) records for pre-travel multidisciplinary clearance.
The standard stay in India is 3 to 4 days, covering baseline multimodal retinal imaging, the cellular procedure, post-procedure ophthalmic checks, and personalized home nutritional support recommendations.
Peer-Reviewed Scientific Citations & Clinical References
Key published clinical trials and peer-reviewed literature supporting cellular therapy in Macular Degeneration:
Mandatory Regulatory & Medical Disclaimer
Non-Restorative Disclosure
Important Medical Notice:
Independent Medical Consultation
Stem cell applications for Macular Degeneration are investigative regenerative procedures aimed at tissue support and functional preservation; they do not constitute a permanent cure or guaranteed restoration of eyesight. Efficacy varies by individual pathology. In India, cell processing and therapeutic protocols follow the National Guidelines for Stem Cell Research under the oversight of institutional ethics committees and national regulatory bodies (ICMR/CDSCO). Patients should evaluate all standard ophthalmological therapies (including anti-VEGF injections and AREDS-2 regimens) with their primary retinal specialist before pursuing regenerative protocols.